C3PO - Convalescent Plasma Study

The Food and Drug Administration has authorized emergency use of convalescent plasma (CP) in patients with COVID-19 who are hospitalized. Early data suggests that CP is most beneficial if given early in the course of illness. The goal of the C3PO study is to test whether giving CP even earlier (before someone is in the hospital) can prevent those with mild COVID-19 from becoming more severe (and prevent hospitalization altogether).

I'm Interested

This research study is led by Dr. Howard Smithline.

Contact: Kye Poronsky, 413-794-8680

Primary Sponsor: NHLBI and NINDS

Participation Details:

August 25, 2020
COVID19, Infection, Emergency medicine
Baystate Medical Center, 759 Chestnut St, Springfield, MA
  1. Being seen in the emergency department
  2. COVID symptoms for no longer than 7 days
  3. Age 18 years or older
  4. Having at least 1 risk factor (hypertension, age equal to or greater than 50 years, diabetes, coronary artery disease, asthma, COPD, immunosuppression, BMI equal to or greater than 30)
  5. Confirmed COVID positive (tested prior to the ED visit, or while in the ED)
3-4 hours during emergency department (ED) visit